Comparative effectiveness of loop diuretics on mortality in the treatment of patients with chronic heart failure – a multicenter propensity score matched analysis
| Autor: | Lutz Frankenstein, Stefan Agewall, Tobias Täger, Dieter Schellberg, Dan Atar, Torstein Hole, Andrew L. Clark, Hugo A. Katus, Hanna Fröhlich, Morten Grundtvig, Mirjam Seiz, Kevin Goode, Syed Kazmi, John G.F. Cleland |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Male
medicine.medical_specialty Blood Pressure 030204 cardiovascular system & hematology Ventricular Function Left 03 medical and health sciences 0302 clinical medicine Sodium Potassium Chloride Symporter Inhibitors Furosemide Internal medicine Cause of Death Medicine Humans Bumetanide Chronic heart failure Loop diuretics Mortality Torasemide In patient 030212 general & internal medicine Propensity Score Aged Retrospective Studies Heart Failure business.industry Stroke Volume Middle Aged medicine.disease Differential effects Torsemide R1 Europe Survival Rate Treatment Outcome Heart failure Propensity score matching Female Cardiology and Cardiovascular Medicine business medicine.drug Follow-Up Studies |
| Zdroj: | International Journal of Cardiology |
| ISSN: | 0167-5273 |
| Popis: | Tager, T., et al. (2019). "Comparative effectiveness of loop diuretics on mortality in the treatment of patients with chronic heart failure - A multicenter propensity score matched analysis." Int J Cardiol 289: 83-90. Abstract BACKGROUND: Loop diuretics are given to the majority of patients with chronic heart failure (HF). Whether the different pharmacological properties of the three guideline-recommended loop diuretics result in differential effects on survival is unknown. METHODS: 6293 patients with chronic HF using either bumetanide, furosemide or torasemide were identified in three European HF registries. Patients were individually matched on both the respective propensity scores for receipt of the individual drug and dose-equivalents thereof. RESULTS: During a follow-up of 35,038 patient-years, 652 (53.7%), 2179 (51.9%), and 268 (30.4%) patients died amongst those prescribed bumetanide, furosemide, and torasemide, respectively. In univariable analyses of the general sample, bumetanide and furosemide were both associated with higher mortality as compared with torasemide treatment (HR 1.50, 95% CI 1.31-1.73, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect